Literature DB >> 20509009

Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases.

Mark A Hoffman1.   

Abstract

Therapy with a purine analogue (cladribine or pentostatin, most often cladribine) has revolutionized the care of patients with hairy cell leukemia, resulting in very long-lasting remissions in the majority of cases. For patients who relapse, re-induction with cladribine again induces durable remissions. For patients with short remission durations, rituximab can be effective, and for a small proportion of patients with more resistant disease, BL22 has been used successfully. I report three cases in which alpha interferon induction and maintenance has produced ongoing remissions in patients with short remission durations after cladribine. One patient had also not responded to rituximab. Alpha interferon may be a very effective treatment option for selected patients with relapsed hairy cell leukemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20509009     DOI: 10.1007/s12032-010-9550-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  11 in total

1.  Alpha interferon for induction of remission in hairy-cell leukemia.

Authors:  J R Quesada; J Reuben; J T Manning; E M Hersh; J U Gutterman
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

2.  Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia.

Authors:  Rudolf Benz; Raffaele Daniele Siciliano; Georg Stussi; Jörg Fehr
Journal:  Eur J Haematol       Date:  2008-12-05       Impact factor: 2.997

3.  Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

Authors:  M Grever; K Kopecky; M K Foucar; D Head; J M Bennett; R E Hutchison; W E Corbett; P A Cassileth; T Habermann; H Golomb
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

Review 4.  Which role for rituximab in hairy cell leukemia? Reflections on six cases.

Authors:  J V Malfuson; T Fagot; J Konopacki; B Souleau; S Cremades; T de Revel
Journal:  Acta Haematol       Date:  2009-12-24       Impact factor: 2.195

5.  Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.

Authors:  J F Seymour; E H Estey; M J Keating; R Kurzrock
Journal:  Leukemia       Date:  1995-05       Impact factor: 11.528

6.  Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Authors:  Monica Else; Claire E Dearden; Estella Matutes; Juan Garcia-Talavera; Ama Z S Rohatiner; Steve A N Johnson; Nigel T J O'Connor; Andy Haynes; Nnenna Osuji; Francesco Forconi; Francesco Lauria; Daniel Catovsky
Journal:  Br J Haematol       Date:  2009-03-29       Impact factor: 6.998

7.  Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.

Authors:  J W Smith; D L Longo; W J Urba; J W Clark; T Watson; J Beveridge; K C Conlon; M Sznol; S P Creekmore; W G Alvord
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

8.  Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin).

Authors:  A S Spiers; S J Parekh; M B Bishop
Journal:  J Clin Oncol       Date:  1984-12       Impact factor: 44.544

9.  Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.

Authors:  E Berman; G Heller; S Kempin; T Gee; L L Tran; B Clarkson
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

10.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

Authors:  L D Piro; C J Carrera; D A Carson; E Beutler
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

View more
  1 in total

Review 1.  Targeting the tumor microenvironment to enhance antitumor immune responses.

Authors:  Kevin Van der Jeught; Lukasz Bialkowski; Lidia Daszkiewicz; Katrijn Broos; Cleo Goyvaerts; Dries Renmans; Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Oncotarget       Date:  2015-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.